The preliminary efficacy of KN026 (Anti-HER2 BsAb) in advanced gastric and gastroesophageal junction cancer patients with HER2 expression.

Jianming Xu(Chinese PLA General Hospital), Ting Xu(Beijing Tian Tan Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaojun Xiang(Ministry of Agriculture and Rural Affairs), Yun Zhang(Harbin Medical University), Yuchen Liu(Zhejiang Chinese Medical University), Juan Liu, Feng Ye(First Affiliated Hospital of Xiamen University), Jianhong Wang(Nantong Tumor Hospital), Jun Wu(The First People's Hospital of Changzhou), Qiong Wu(Shanghai East Hospital), Baohong Guo, Yanqiao Zhang(Harbin Medical University), Rusen Zhao(Central Hospital of Zibo), Nong Xu(First Affiliated Hospital Zhejiang University), Shuning Xing
Journal of Clinical Oncology
May 20, 2021
10.1200/jco.2021.39.15_suppl.e16005
Cited by 13

Related Papers

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
|Nature|2021|687